Here is the complete patent application following the provided outline:

# DESCRIPTION  

## BACKGROUND  

Chromosomal translocations play a significant role in the pathogenesis of various genetic disorders, particularly hematologic malignancies such as chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ B-ALL). The Philadelphia chromosome results from a reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34;q11), which generates the BCR-ABL1 fusion gene. This fusion gene encodes a constitutively active tyrosine kinase that drives oncogenic transformation.  

Current diagnostic methods for detecting BCR-ABL1 translocations include karyotyping, fluorescence in situ hybridization (FISH), and reverse transcription polymerase chain reaction (RT-PCR). Karyotyping requires metaphase cells obtained from bone marrow cultures, limiting its applicability to peripheral blood samples. FISH, while applicable to non-dividing cells, lacks the resolution to precisely identify breakpoints at the nucleotide level. RT-PCR detects fusion transcripts but is susceptible to RNA degradation and transcriptional silencing, potentially yielding false-negative results.  

There remains an unmet need for a robust, DNA-based method capable of precisely identifying translocation breakpoints without requiring cell culture or being hindered by RNA instability. Such a method would provide a stable biomarker for disease diagnosis, monitoring minimal residual disease, and assessing treatment response.  

## SUMMARY OF THE INVENTION  

The present invention provides a novel method termed "Anchored ChromPET" (Chromosomal Paired-End Tag) for detecting chromosomal translocations, particularly the BCR-ABL1 translocation in CML and Ph+ B-ALL. The method combines targeted genomic capture, paired-end sequencing, and bioinformatic analysis to precisely identify translocation breakpoints at single-nucleotide resolution.  

Key aspects of the invention include:  
1. **Targeted Capture**: Enrichment of genomic regions of interest (e.g., the major breakpoint cluster region (M-bcr) of BCR) using biotinylated RNA baits.  
2. **Paired-End Sequencing**: Construction of a ChromPET library with barcoded adapters, enabling multiplexed sequencing of multiple samples in a single sequencing run.  
3. **Bioinformatic Analysis**: Computational prediction of translocation breakpoints using junctional ChromPETs and validation via PCR amplification and sequencing.  

The method offers several advantages over existing techniques:  
- High sensitivity (detection at 0.01% mutant allele frequency).  
- Single-nucleotide resolution of breakpoints.  
- Applicability to non-dividing cells and archived samples (e.g., formalin-fixed paraffin-embedded tissue).  
- Generation of patient-specific DNA biomarkers for long-term monitoring.  

## DETAILED DESCRIPTION OF THE INVENTION  

The Anchored ChromPET method involves three major steps: (1) library preparation, (2) targeted capture, and (3) sequencing and bioinformatic analysis.  

### Library Preparation  
Genomic DNA is fragmented, end-repaired, and ligated to Y-shaped adapters containing sample-specific barcodes. The library is size-selected (e.g., 500 bp fragments) and amplified using primers complementary to the adapter sequences.  

### Targeted Capture  
A biotinylated RNA bait is synthesized to target the genomic region of interest (e.g., the 6.6 kb M-bcr region of BCR). The RNA bait is hybridized to the ChromPET library, and RNA-DNA hybrids are captured using streptavidin-coated magnetic beads. Non-hybridized DNA is washed away, and the enriched DNA is eluted for sequencing.  

### Sequencing and Analysis  
The enriched library is subjected to paired-end sequencing (e.g., 38 bp reads). Sequencing reads are demultiplexed using barcodes and mapped to reference genomes (BCR and ABL1 loci). Junctional ChromPETs spanning the translocation breakpoint are identified, and breakpoints are predicted using a voting algorithm based on fragment size distribution.  

### Abbreviations and Acronyms  
- **CML**: Chronic myeloid leukemia  
- **Ph+ B-ALL**: Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia  
- **FISH**: Fluorescence in situ hybridization  
- **RT-PCR**: Reverse transcription polymerase chain reaction  
- **M-bcr**: Major breakpoint cluster region  
- **ChromPET**: Chromosomal paired-end tag  

## DEFINITIONS  

1. **Anchored ChromPET**: A method combining targeted genomic capture with paired-end sequencing to identify chromosomal translocations.  
2. **RNA Bait**: Biotinylated RNA probes complementary to a genomic region of interest, used for targeted enrichment.  
3. **Junctional ChromPET**: A paired-end read spanning a translocation breakpoint.  
4. **Breakpoint Prediction Algorithm**: A computational method to identify the most probable translocation breakpoint using junctional ChromPETs.  

## EMBODIMENTS  

1. A method for detecting chromosomal translocations comprising:  
   a. Preparing a ChromPET library from genomic DNA.  
   b. Enriching target regions using RNA bait.  
   c. Sequencing the enriched library.  
   d. Identifying junctional ChromPETs and predicting breakpoints.  

2. The method of embodiment 1, wherein the translocation is BCR-ABL1.  

3. The method of embodiment 1, wherein the RNA bait targets the M-bcr region of BCR.  

4. The method of embodiment 1, wherein the ChromPET library is multiplexed using barcoded adapters.  

5. The method of embodiment 1, further comprising validating breakpoints by PCR and sequencing.  

## EXAMPLES  

### Reagents  
- APex Heat-Labile Alkaline Phosphatase (Epicentre)  
- Biotin-16-UTP (Roche)  
- DNAZol reagent (Invitrogen)  
- Dynabeads M-280 streptavidin (Invitrogen)  
- End-It DNA End Repair Kit (Epicentre)  

### Table 1 (Comprising Tables 1A and 1B). Number of ChromPETs Sequenced, Mapped, Anchored to BCR and Junctional for Each Sample (A) Cell Lines and (B) Patient Samples  

**Table 1A: Cell Lines**  
| Sample  | Total Reads | BCR-Anchored | Junctional ChromPETs |  
|---------|------------|--------------|-----------------------|  
| K562    | 1,600,000  | 21,798       | 1,004 (4.6%)          |  
| KU812   | 1,600,000  | 15,432       | 308 (2.0%)           |  

**Table 1B: Patient Samples**  
| Sample  | Total Reads | BCR-Anchored | Junctional ChromPETs |  
|---------|------------|--------------|-----------------------|  
| PS1     | 250,000    | 1,204        | 23 (1.9%)            |  
| PS2     | 250,000    | 403          | 8 (2.0%)             |  
| PS3     | 250,000    | 512          | 0 (0%)               |  

## CONCLUSIONS  

The Anchored ChromPET method provides a highly sensitive and precise approach for detecting chromosomal translocations, particularly BCR-ABL1 in CML and Ph+ B-ALL. By combining targeted capture, paired-end sequencing, and bioinformatic analysis, the method identifies breakpoints at single-nucleotide resolution and generates patient-specific DNA biomarkers.  

Key advantages include:  
- Elimination of the need for cell culture.  
- Superior stability of DNA compared to RNA.  
- Applicability to archived and low-quality samples.  
- Scalability for high-throughput clinical diagnostics.  

This invention represents a significant advancement in the molecular diagnosis and monitoring of hematologic malignancies and other diseases caused by chromosomal translocations.